# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-21-000058
Filing Date
2021-04-23
Accepted
2021-04-23 16:09:26
Documents
11
Period of Report
2021-06-04

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ligand-2021annualmeetingpr.htm | DEF 14A | 844447
2 |  | image1.jpg | GRAPHIC | 14261
3 |  | image_01.jpg | GRAPHIC | 12141
4 |  | image_101.jpg | GRAPHIC | 510098
5 |  | image_111.jpg | GRAPHIC | 475488
6 |  | image_21.jpg | GRAPHIC | 268584
7 |  | image_31.jpg | GRAPHIC | 230720
8 |  | image_41.jpg | GRAPHIC | 72304
9 |  | image_91.jpg | GRAPHIC | 537811
10 |  | proxycard1of21a.jpg | GRAPHIC | 168272
11 |  | proxycard2of21a.jpg | GRAPHIC | 172237
| Complete submission text file | 0000886163-21-000058.txt |  | 4214835

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 21849795
SIC: 2834 Pharmaceutical Preparations